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Introduction
Frailty is a major public health concern in the older 
population and a leading cause of premature mortality and 
functional decline (1). The prevalence of frailty increases with 
age and tends to affect women more than men (1-5). Based 
on a meta-analysis of Europeans, the prevalence of frailty 
is estimated to be 15% for individuals aged 65 and over (6), 
and 25% for individuals aged over 85 years (7). The older 
adult population within indigenous communities with a low 
socioeconomic status are estimated to have a frailty prevalence 
>50% (8,9). This health burden is predicted to grow alongside 
an increasing and ageing population (1,3). Despite the increase 
in prevalence with age, signs of frailty can develop before the 
age of 65 years (10). On the other hand, many aging adults 
do not develop frailty, which suggests that it is not part of the 
normal ageing process and can therefore be prevented (11). 
There are several frailty definitions (5). Frailty can 
be defined as a clinical state where the individuals may 
become more vulnerable to external stressors, thereby 
enhancing their risk of experiencing an adverse event such 
as functional dependency or death (3,12). Frailty develops 
as a consequence of an exposure to various factors including 
physiological changes and/or illnesses associated with aging, 
sarcopenia, polypharmacy, living sedentary lifestyles, poverty, 
and social isolation (11,13-15). It is a dynamic process that 
can transition between different levels of severity (mild to 
severe), particularly in the early stages of development (1). 
Early identification and management of frailty is of paramount 
importance as it may improve functional independence (4, 
11). This can be achieved by implementing screening tools 
and treatment protocols from high quality clinical practice 
guidelines (CPGs).
CPGs are needed for frailty to ensure patients receive 
the best care. CPGs are recommendations informed by 
evidence (16). The aim of CPGs is to provide guidance to 
healthcare practitioners on the treatment strategies that will 
be most beneficial to the patient and thus removing the risk of 
treatments being ineffective or having adverse effects (17). A 
panel of experts with a relevant clinical background is formed 
to develop CPGs (16). A systematic review performed by these 
experts looks at the methodological quality of studies, the 
certainty of evidence, and the strength of recommendations to 
be made (18). CPGs are then formulated taking into account 
certain practical considerations such as resources, benefits 
(vs. harms), the values of the patient, stakeholders opinion, 
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and how feasible it is to provide/follow the recommendation 
(18). CPGs for frailty are required to provide clinicians with 
applicable standards of care (2). Currently, CPGs for frailty are 
aimed at identifying frailty (and its causes); however, there is 
a lack of definitive standards for managing frailty (2). CPGs 
aim to improve identification of individuals with frailty and 
provide the best management strategies, in order to ensure 
older individuals with frailty receive the best evidence-based 
care leading to the best possible outcomes (2). Therefore, 
the aim of this systematic review was to identify consistent 
recommendations for screening, assessment, and management 
of frailty from CPGs for use by healthcare providers.
Methods
This systematic review was conducted and reported in 
accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines.
Search strategy
A systematic literature search was performed independently 
by reviewers (AMA/JB/LH/GL/CL/SKP) on Ovid MEDLINE, 
Embase, PubMed, PsycINFO, and Cumulative Index to Nursing 
and Allied Health Literature (CINAHL) as these electronic 
databases were determined to be the most comprehensive 
databases of medical, nursing, and allied health journals. The 
databases PEDro and Scopus were initially considered but 
Table 1
Search strategy
a) Database search strategy
Theme 1 Guidelines AND Theme 2 Frailty
1. explode guideline/ 1. explode “frailty” all subheadings
2. guidelines as topic/ 2. Frail*
3. explode practice guideline/ 3. Pre-frail*
4. practice guidelines as topic/ 4. Mild frail*
5. health planning guidelines/ 5. Pre frail*
6. explode treatment guidelines/ 6. Prefrail*
7. (standards or guideline or   guidelines).ti,kf,kw. 7. “frailty/diagnosis”
8. ((practice or treatment* or clinical) adj guideline*).ab. 8. “frailty/therapy*”
9. Clinical Practice Guidelines
10. (CPG or CPGs).ti.
b) Grey literature search strategy
Country Websites searched Links to sites
Australia Australian Clinical Practice Guidelines https://www.clinicalguidelines.gov.au/
Australia Australian National Health and Medical Research 
Council
https://www.nhmrc.gov.au/health-advice/guidelines
Canada Canadian Medical Association Infobase of Clinical 
Practice Guidelines
https://joulecma.ca/cpg/homepage
International Guidelines International Network (G-I-N) http://www.g-i-n.net
New Zealand New Zealand Guidelines Group https://www.health.govt.nz/about-ministry/ministry-health-web-
sites/new-zealand-guidelines-group
United Kingdom British Geriatrics Society https://www.bgs.org.uk   
United Kingdom eGuidelines www.guidelines.co.uk 
United Kingdom National Library for Health on Guidelines Finder https://www.evidence.nhs.uk/search?q=guidelines+finder
United Kingdom National Institute for Clinical Excellence https://www.nice.org.uk/
United Kingdom Scottish Intercollegiate Guidelines Network https://www.sign.ac.uk/ 
United Kingdom World Confederation for Physical Therapy https://www.wcpt.org/ 
United States American Geriatrics Society https://www.americangeriatrics.org/
United States Gerontological Society of America https://www.geron.org/
United States Guideline Central https://www.guidelinecentral.com/summaries/frailty-in-elder-
ly-people/#section-society
United States The National Guideline Clearinghouse https://www.ahrq.gov/gam/index.html
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then eliminated due to a high yield of non-specific results. 
Database-specific search terms including, but not limited to, 
keywords and MeSH headings were used under two broad areas 
“guidelines” and “frailty” to search the databases (Table 1a). 
A manual search was also performed via websites of guideline 
databases with the key phrase “frailty guideline”, in order to 
expand the search and thus capture guidelines not found in 
the databases search. A full list of the websites of guideline 
databases searched are provided in Table 1b. Filters applied 
to the search strategy included full text, age range >65 years, 
English language, and updated since 1st Jan 2010 as older 
studies could provide out-of-date recommendations. 
Eligibility criteria
CPGs  were  inc luded  i f  t hey  ( i )  summar ized 
recommendations in English for screening, assessment, and 
management of frailty; (ii) targeted individuals aged >65 years; 
(iii) operationally defined frailty as a discrete clinical entity that 
is distinct from disability (impairment leading to restrictions 
in activities of daily living [ADLs]) and comorbidity (the 
coexistence of two or more chronic diseases), when three or 
more of the following five phenotypic criteria are present: 
weakness measured by low grip strength; slowness measured 
by decreased walking speed; a low level of physical activity; 
low energy or self-reported exhaustion; unintentional weight 
loss.(5) Articles were excluded if they were (i) CPGs guidelines 
not specifically focusing on screening, assessment, and 
management of frailty; (ii) CPGs targeting adults aged 18-64 
years; (iii) primary studies; and (iv) secondary studies (other 
than CPGs of interest).
CPGs selection process
Articles obtained through electronic search were exported 
to EndNote-X9 reference-manager. A multi-stage screening 
process was applied to select CPGs. Two independent reviewers 
(AMA/JB/LH/GL/CL/SKP) screened the titles, abstracts, and/
or full text of all articles against the eligibility criteria. Any 
disagreement between the two reviewers were resolved by 
discussion and/or consultation with a third reviewer (PM/DW) 
to arrive at a consensus. 
Data extraction 
Data were extracted independently by one reviewer and 
subsequently verified by a second reviewer in a paired 
group (AMA/JB/LH/GL/CL/SKP). Data extracted included 
the following demographic information: country of origin; 
professional composition panel; the aim of CPGs; year of 
publication and last update; target population, target audience/
users, and specific recommendations (Table 2). In this review, 
the primary outcome measures were recommendations for 
screening, assessment, and management of frailty summarized 
in the CPGs. There was no secondary outcome measure chosen 
for this review.
Quality assessment of CPGs
The Appraisal of Guidelines Research and Evaluation 
(AGREE) II instrument was used to determine the quality of 
development for each included guideline (19). The AGREE II is 
the international gold standard to evaluate and develop practice 
guidelines (20,21). This instrument considers the reporting of 
23 items organized within six domains followed by an overall 
assessment, which includes the rating of the overall quality of 
the guideline (19). Many countries have used the AGREE II 
instrument based on its universal value to evaluate and validate 
the methodological quality of CPGs, including CPGs for the 
management of specific diseases (22-25). 
Each of the AGREE II items and the global rating items are 
rated on a 7-point scale (1– strongly disagree to 7–strongly 
agree) (19). A set of three reviewers (AMA/JB/LH/GL/CL/
SKP & PM/AA) independently graded and calculated the 
methodological quality of the individual guidelines according 
to the criteria provided in the AGREE II manual (Table 3) 
(19). The agreement between these three reviewers was 
calculated using the intraclass correlation coefficients (Table 4). 
Disagreements with scores were consulted with an independent 
reviewer (DW) to arrive at a consensus. Further, we classified 
high-quality CPGs as those that had an AGREE II score equal 
to or greater than 50% of the maximum possible score in 
three domains: rigour of development (domain 3), editorial 
independence (domain 6) and stakeholder involvement (domain 
2) (26). 
Evidence summary
Following data extraction, recommendations were compiled 
and compared to identify the key recommendations that are 
consistent among the included CPGs irrespective of their 
methological quality. Recommendations were initially grouped 
into subject topics to identify similarities. The topics of interest 
were identifying frailty, tests used in frailty assessment, frailty 
definition criteria, comorbidities/complications, change in 
frailty status, physical activity, oral health and nutrition, 
monitoring frailty, mood/behavior, polypharmacy, staff/health 
professionals, and crisis management (Table 5). Inconsistent/
conflicting recommendations among the included CPGs were 
excluded from key recommendations in order to identify 
consistent recommendations, along with recommendations only 
made by one CPG.
Results
Systematic search results and characteristics of included 
guidelines
The systematic search process and screening are illustrated 
in Figure 1. The initial search strategy yielded 938 articles via 
online databases and 226 articles via manual database searches 
for CPGs. After excluding 254 duplicates, the remaining 910 
articles were screened for eligibility. Only six CPGs (1-4,27,28) 
met the inclusion criteria and the reasons for exclusion of the 
remaining articles are summarized in Figure 1.
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Figure 1
Adapted PRISMA flow diagram
Characteristics of included CPGs
Characteristics of the included CPGs in this systematic 
review are summarized in Table 2. The country of origin 
varied between the CPGs, with one CPG originating from 
each of the following countries/regions: Australia, British 
Columbia Canada, Italy (Regione Toscana), New Zealand, 
the Asia-Pacific region, and the United Kingdom. All the 
CPGs (n=6) were published or updated within the last 5 years 
(1-4,27,28). All the CPGs (n=6) indicated the management 
of frailty to be their aim, with half of these (n=3) indicating 
the identification of frailty as an additional aim (1-3).  Each 
CPG defined a slightly different target population with over 
half (n=4) of the guidelines specifying the target population 
to be those living with frailty (1-4); however, only two of 
them included those individuals at risk of frailty (1,3), while 
the remaining two CPGs defined their target population to 
be the ‘old’ and ‘ageing’ population respectively (27,28). 
Half of the CPGs (n=3) did not delineate the coexistence 
of co-morbidities alongside frailty in their target population 
(2-4). Of the remaining half, only one included those suffering 
from co-morbidities (27), the other two excluded such 
populations (1,28). All the CPGs (n=6) defined the target 
Table 2
Overview of the Clinical practice guidelines (CPGs) included in this review (n=6)
Ref Title (Reference) Country of Origin Year established Year updated Aim of CPG Target population Target users of CPG
1 Physical Frailty: ICFSR 
International CPGs for Iden-
tification and Management (1)
Australia 2019 NA Overview the current 
evidence-base to provide 
recommendations for 
the identification and 
management of frailty in 
older adults
All older adults with 
frailty or at risk of 
frailty, and not those who 
already have an establi-
shed disability
Health professionals 
who contribute to the 
care of older people 
with frailty, including 
clinicians and allied 
health professionals
2 Frailty Care Guides NZ (27) New Zealand 2019 2020 Complement best practice 
and promote early inter-
vention and communi-
cation with the person’s 
health care team.
Individuals who are 
ageing and/or those with 
multiple co-morbidities
Health care providers
3 The Asia- Pacific CPGs for 
the Management of Frailty (2)
Asia/Pacific 
countries
2017 NA Screening, assessment and 
management of frailty
Older adults with frailty 
in the Asia-Pacific region
Health practitioners in 
the Asia-Pacific region
4 Frailty in Older Adults – 
Early Identification and 
Management (3)
British Columbia 2017 NA Facilitate individualized 
assessment and provide 
framework and tools to 
promote patient-centered 
strategies to manage frailty 
and functional decline 
Older adults with frailty 
or vulnerable to frailty
Primary focus of the 
guideline is the com-
munity-based primary 
care setting
5 Fit for Frailty (4) United Kingdom 2014 2017 To support health and 
social care professionals 
in the community, outpa-
tients’ clinics, community 
hospitals and intermediate 
care settings and older 
people’s homes.
Individuals with frailty Health and social care 




care settings, and in 
older people’s own 
homes
6 Frailty in Elderly People (28) Italy 2013 2015 Provide tools to identify 
frail subjects and provide 
indications on possible 
interventions to prevent 
disability.
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users of their recommendations to be healthcare provider. 
(1-4,27,28). The CPG by Bavazzano et al. (2013) is the only 
one that defined the specific healthcare professionals targeted 
to follow their recommendations (28). One third of the CPGs 
(n=2) also included the specific setting for employing their 
recommendations (3,4).
Quality appraisal of CPGs
Figure 2 displays each of the six domains of the AGREE 
II instrument, and the methodological quality score of each of 
them. Inter-rater agreement for methodological qualiy scores 
was ‘fair’ for editorial independence (domain 6); ‘good’ for 
clarity of presentation (domain 4) and applicability (domain 
5); and ‘excellent’ for all other domains and overall AGREE II 
score (Table 4).
In general, three CPGs generally scored well in each domain 
(1,2,28), whilst the remaining three scored poorly (3,4,27). The 
mean (SD) average scores of all domains of all the included 
CPGs are as follows: domain 1 (‘scope and purpose’) - 84.5% 
(12.39), followed by domain 4 (‘clarity of presentation’) - 
81.5% (12.44), domain 2 (‘stakeholder involvement’) - 68% 
(18.84), domain 6 (‘editorial independence’) - 58.17% (23.03), 
domain 5 (‘applicability’) - 56.3% (20.89), and finally domain 3 
(‘Rigour of Development’) - 4.67% (1.5) (Table 3). 
Figure 2
AGREE II domain-based percentage scores of all the included 
clinical practice guidelines (n=6). Domain 1: scope and 
purpose, domain 2: stakeholder involvement, domain 3: rigour 
of development, domain 4: clarity of presentation, domain 5: 
Applicability, domain 6: editorial independence
Table 3
Summary of AGREE II evaluations














1 Physical Frailty: 
ICFSR Interna-
tional CPGs for 
Identification and 
Management (1)
93 87 75 85 70 65 6 Yes
2 Frailty Care Guides 
NZ (27)
67 40 20 59 44 79 4 Yes, with modifications
3 The Asia- Pacific 
CPGs for the 
Management of 
Frailty (2)
73 75 65 93 65 59 5 Yes, with modifications
4 Frailty in Older 
Adults – Early 
Identification and 
Management (3)
93 68 28 86 70 59 5 Yes, with modifications 
5 Fit for Frailty (4) 83 52 15 76 19 14 2 No
6 Frailty in Elderly 
People (28)
98 86 76 90 70 73 6 Yes
Mean 84.50 68 46.50 81.50 56.33 58.17 4.67
(SD) (12.39) (18.84) (28.50) (12.44) (20.89) (23.03) (1.50)
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Appraisal of CPGs: inter-rater agreement
Table 4
Inter-rater agreement for AGREE II domains and overall 
scores
Domain ICC (95% CI)
Scope and purpose 0.925 (0.71-0.99)
Stakeholder involvement 0.903 (0.62-0.98)
Rigor of development 0.918 (0.65-0.99)
Clarity of presentation 0.858 (0.39- 0.98)
Applicability 0.870 (0.51-0.98)
Editorial independence 0.680 (0.01-0.95)
Overall rating 0.921 (0.67-0.99)
AGREE, Appraisal of Guidelines for Research and Evaluation; CI, confidence intervals; 
ICC, intraclass correlation coefficients.
 
Summary of recommendations
From the six CPGs included in this systematic review, 
a total of fifty-four recommendations were recorded. 
Recommendations suggested by two or more CPGs included 
in this systematic review are displayed in Table 5. Three 
of the recommendations were contradicting each other and 
therefore were excluded from Table 5. Seventeen of the 
recommendations (32%) could not be grouped/related to a 
recommendation from another CPG and therefore were also 
excluded from Table 5. No recommendations on how not to 
screen/assess or manage/treat a patient could be grouped/related 
to a recommendation from another CPG and therefore they 
were excluded in Table 5. (Supplementary material- Appendix 
1)
Discussion
This study aims to corroborate consistent recommendations 
from CPGs for frailty screening, assessment and management. 
We identified six frailty CPGs based on the current evidence 
from 2010 until now. The mean scores for the six AGREE II 
domains (scope and purpose, stakeholder involvement, rigor of 
development, clarity of presentation, applicability, and editorial 
independence) were 84.50%, 68%, 46.50%, 81.50%, 56.33%, 
58.17%, and 4.67% respectively. The overall quality of the 
CPGs was good for the majority of the CPGs reached an overall 
guideline quality between 4 and 6 points.
Main findings and AGREE II methodological quality 
appraisal
Assessment of the ‘scope and purpose’of CPGs is required 
to evaluate if there is a clear definition of the objective of the 
CPG, to allow health professionals to determine if the CPG 
is likely to contain information relating to how they would 
manage a patient who has been diagnosed with frailty (19). 
Whilst all CPGs included in this systematic review achieved 
an AGREE II rating of above 50% (Figure 2), three CPGs 
particularly excelled in achieving high quality ‘scope and 
purpose’ ratings, of greater than 90% (1,4,28). A limitation 
of these three CPGs is a lack of specific identification of a 
target population (1,4,28). Specifying the target population 
would increase the relevance and significance of the 
recommendations. The three other CPGs achieved AGREE II 
scores of less than 70% for this domain (2,3,27). 
‘Stakeholder involvement’ is an important step in framing 
CPGs, with multi-disciplinary stakeholders having first-hand, 
practical knowledge of the condition for which these guidelines 
will be applied. The CPGs included in this review had a varied 
level of stakeholder involvement with some achieving an 
AGREE II rating as low as 40% (27), and others as high as 87% 
(28). Although the majority of the CPGs successfully included 
a list of the stakeholders (1-4,28), each guideline failed to 
specify their role in the developmental process of the guideline 
(1-4,27,28). Consequently, it was difficult to determine if the 
guidelines had been formed with clinical applicability in mind. 
Furthermore, the target audience was not specifically defined 
in the CPGs, with the guidelines broadly defining the intended 
users as healthcare providers (1-4,27). The CPG of Bavazzano 
et al. (2013) is the only one to provide a clear definition that 
specifies the healthcare professionals that the guideline is 
intended to be used by (28). These findings explain the large 
variability in overall scores for stakeholder involvement in 
accordance with the AGREE II guideline. 
Investigation into the ‘rigour of development’ of the CPGs 
revealed polarizing results. Three CPGs stated a protocol of 
how their recommendations and guidelines were finalized, with 
various experts discussing the strengths and weaknesses of 
current clinical guidelines for frailty (1,2,5). Results were then 
formalized as recommendations in the management of frailty 
guidelines (1,2,5). A risk analysis was performed on these 
recommendations to ensure safe application of these guidelines 
in clinical practice (1,2,5). On the contrary, a limitation in 
the development of the remaining three CPGs was the failure 
to disclose a systematic method for data collection.(3,4,12). 
Additionally, there were no criteria for selecting current frailty 
guidelines (3,4,12). Furthermore, there was no description of 
how or when these recommendations will be updated (3,4, 
12). The CPGs inclusion/exclusion of methods is reflected 
in Figure 2. A rigorous developmental process elucidating 
how recommendations are established and framing a working 
template as to how frailty guidelines could be updated are 
warranted in future CPGs.
The ‘clarity of presentation’considers the overall 
structure and formatting of a guideline, and whether each 
recommendation is coherent and written with precision 
(19). All the CPGs achieved an AGREE II score of 50% or 
above, with four CPGs scoring over 85% as shown in Figure 
2. Despite the high AGREE II scores for domain four, five 
out of six CPGs shared a common limitation (1-4,28). Most 
guideline developers failed to establish recommendations that 
consistently specified an age group within the frail population 
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(1-4,27). Consequently, this has created uncertainty as to 
which population the recommendations listed in these CPGs 
are relevant to. Providing the age group, stage, and severity 
of frailty in each recommendation will enhance specificity 
and relevance. Key recommendations were easily identifiable 
in five of the CPGs, presented in either a box, table, or in 
bold text (1-4,28). However, the guidelines formulated by the 
Health Quality and Safety Commission neglected to include 
a summary of the key recommendations, thus resulting in 
a guideline that was difficult to assess and assimilate (27). 
This limitation is reflected in the AGREE II score where it 
was ranked lowest in terms of the ‘clarity of presentation’. 
Providing the target audience with a clearly labelled list of 
key recommendations will not only save the user time, but 
also allow them to consider whether they are relevant to their 
patient.
‘Applicability’ evaluates how CPGs describe the application 
of the recommendation in a healthcare setting (19). To facilitate 
its ongoing use, CPGs with relatively high ‘applicability’ scores 
will provide the health professional with tools and resources 
to improve their practice efficiency and enhance their patient 
care for the frail population (19). In this systematic review, 
three CPGs achieved an AGREE II score of 70%, whilst two 
of the remaining CPGs scored less than 50% (Figure 2). Three 
CPGs did not identify the facilitators or barriers involved in 
the implementation of these guidelines (2-4). Two CPGs did 
not disclose cost implication for health care budgets (2,27). 
For three CPGs, there was no risk/benefit analysis about their 
recommendations, which is a key tool that clinicians would 
use to determine the applicability of the guidelines in clinical 
practice (3,4,12). Tools and resources enhance professional 
competency and provide information regarding implementing 
guidelines into practice, and this was missing in the other 
three CPGs (1,4,28). Another limitation was all CPGs failed 
to mention how they would monitor and audit to increase 
the specificity, and therefore, the relevance of the guidelines 
(1-4,27,28). Due to lack of setting an ‘applicability’ threshold, 
the CPGs included in this review fail to provide strong and 
relevant recommendations for future use.
We found no consistency among the six guidelines about 
documentation of ‘Editorial Independence’. Three CPGs did 
not provide any documentation about funding bodies or related 
conflicts of interest (2-4). One guideline did provide the name 
of the funding body, but there was no description regarding 
any conflict of interest between each member of the guideline 
development group (27). Only two CPGs specified conflicts 
Table 5
Overview of recommendations within the clinical practice guidelines (CPGs)
Key recommendation Number of CPGs that recommended Recommendation classification
Screening/assessment
1. On all encounters with healthcare professionals’ older people should be screened, or offered 
screening to identify if frailty is related to their condition
4 Should do
2. Elderly subjects should be considered pre-frail and offered screening if presenting with clinical 
features 
3 Could do
3. Gait speed is a recommended outcome measure for frailty assessment 3 Could do
4. A validated measurement tool should be used to assess frailty 2 Unsure 
Management/treatment 
5. Physical activity should be used to manage the effects of frailty 3 Could do
6. All reversible medical conditions should be addressed in care of patient 3 Could do
7. Monitoring diet and bodyweight is an important aspect of managing frailty 3 Could do
8. All aspects of a patient’s frailty condition should be monitored with regular reviews and 
updates
3 Could do
9. A comprehensive management plan should be created to outline care of the patient and shared 
with friends and family
3 Could do
10. Patients medication should be reviewed routinely; avoid and decrease polypharmacy 3 Could do
11. Vitamin D supplementation is only recommended in vitamin D deficient patients 2 Unsure 
12. Unintentional weight loss and undernutrition should be treated by protein/caloric supplemen-
tation
2 Unsure 
13. Resistance training is specifically recommended for management of frailty 2 Unsure 
14. Patients should be referred to geriatric specialists when they have multiple conditions (comor-
bidities) besides frailty
2 Unsure 
15. Patients with comorbidities besides frailty require different treatment compared to patients with 
a singular condition
2 Unsure 
16. Advanced care plans should be well established and understood before they are needed to be 
put in action
2 Unsure 
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of interest between each author and the funding body (1, 28). 
Elaborating the influence that these conflicts had on guideline 
development would have further enhanced the transparency 
of the guidelines, to ensure the effects of bias are apparent in 
developement of the CPG. 
Implications from consistent key recommendations of 
CPGs for frailty
Key recommendations were divided into two broad 
categories of screening recommendations and management/
treatment recommendations (Table 2).The CPGs for screening 
protocol varies between sources, providing no one standardized 
measurement tool, which could make inter-clinician 
communication challenging (1-4,5,11). Implementation 
of frailty screening can potentially be time consuming for 
clinicians, depending on which protocol is followed (39). CPGs 
suggest that during consultation between clinician and older 
patients, clinicians should be alert to potential frailty signs 
(1,2,4,11). Older patients that undergo regular checkups could 
easily be identified; however, how effective clinicians are at 
detecting frailty is unclear (39).
Management/treatment guidelines involved largely some 
form of physical exercise, diet management and regular 
checkups (1-5,11). How feasible these are for patients is unclear 
and can be circumstantial. Access to exercise area/equipment, 
the ability to clinically supervise the patient, and fear avoidance 
behaviors can play a role in choosing or performing physical 
exercises (2). Another example includes diet which can be 
influenced by living circumstances (11). Patient knowledge 
and cognition, financial situation, physical ability or personal 
preferences can impact how well the CPG is followed. A 
comprehensive management plan can easily be provided by 
clinicians,which can be altered to suit the resources available to 
each individual patient (2). However, adherence to the program 
will differ between patients (2). It is unclear whether the CPGs 
in this review looked at how difficult it would be to carry out 
the recommendations and this could be an area for further 
research.
Global Context
It has been well established in previous literature that the 
aging population is expected to have a significant impact on 
the health care sector (29-31). In 2018, it was the first time 
in the world history where the population aged over 65 years 
was greater than that aged under five (32). Unfortunately, this 
trend is not reflected by the number of medical professionals 
practicing in aged versus youth care; for example, in 2016, 
there were only 619 registered geriatricians (33) compared 
to 2059 pediatricians in Australia (34). In the United States, 
there were only 6,952 board certified geriatricians in 2018. The 
majority of CPGs included in this systematic review originate 
from higher economic status countries, which is paralleled 
by the old-age dependency ratio, defined as the proportion 
of people aged older than 64 years compared to people in 
the working-age group aged 15-64 years (32). Therefore, 
CPGs included in this review reflect countries and economies 
with the highest need for guidelines. Further research should 
explore how CPGs are being implemented in clinical practice, 
because currently there is only theoretical literature that does 
not address the clinical impact of available CPGs and the 
relevant recommendations. With frailty being a reality for 
so many people in their older age, it is imperative that clear 
recommendations and procedures are implemented into clinical 
practice worldwide to reduce the length of hospital stay, the 
cost of frailty, the effect on quality of life, and impact on each 
older person’s independence.
By 2050, the world’s population aged 60 years and over is 
predicted to reach 2 billion, a significant rise from 900 million 
people in 2015 (35,36). A substantial proportion of the older 
population will experience frailty, resulting in an increase in 
demand for healthcare resources (35). According to Bock et 
al. (2016), the cost for three months of healthcare for older 
adults with frailty is $4000USD, which is approximately five 
times higher than the cost for non-frail older adults (29). These 
healthcare expenses reveal the importance of delivering care 
effectively and efficiently. It is important to consider that 
specific screening tools and interventions to manage frailty may 
not be feasible in settings where there are limited resources, and 
it is in these situations where we need to offer cost-effective 
alternatives for screening and treatment (1). Furthermore, it 
is important to identify whether a CPG is relevant to ensure 
resources are being utilized appropriately.(19) Upon assessment 
of the ‘clarity of presentation’, management options for frailty 
were successfully reported in all CPGs (1-4,27,28). It is advised 
that guidelines containing recommendations for management 
of a health issue, such as frailty, should report options for 
screening, analysis and treatment management (19). This allows 
health practitioners to select the most appropriate screening 
tool and treatment, based on multiple factors, in particular, 
availability of resources, and cost-effectiveness. Regarding 
the “assessment of applicability”, resource implications were 
not disclosed in two of the six CPGs (2,27). It is a requirement 
that CPGs include an analysis on the potential impact a 
recommendation has on resources (19). Each recommendation 
may require numerous resources, such as specialised health 
practitioners and sophisticated equipment (19). Consequently, 
these additional resources will have cost implications for 
healthcare (19).
There is conflicting evidence to suggest that screening 
tools are cost-effective (1). Bleijenburg et al. (2017) reported 
that proactive screening for frailty in a primary care setting 
had a high probability of being cost-effective, as opposed 
to usual care (37). However, a recent study concluded that 
frailty screening is unlikely to be cost-effective (38). Despite 
these findings, our study found four out of the six CPGs 
recommended that older people should be screened or offered 
screening to identify if frailty is related to their condition 
(1,3,4,28). These conflicting results suggest that further 
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research around the cost-effectiveness of frailty screening is 
needed. 
Strengths and limitations 
An extensive search strategy was carried out and 
comprehensive methods for screening and selecting CPGs 
were applied to reduce bias. There are some key limitations 
in the development of this systematic review. The first is 
the reliability of scoring methological quality of CPGs with 
the AGREE II instrument. Evaluating the methodological 
quality of a guideline requires each reviewer to provide a score 
based on a list of criteria within the AGREE II instrument 
(19). Consequently, each score is subjective and could pose 
potential bias on decisions about guideline recommendations 
(19). However, a strength of this review is the good-to-excellent 
ICC values between all the three ratings for the majority of 
items, except for editorial review, which was reported to be 
average. Further, it is important to consider that the AGREE 
II instrument fails to differentiate between low or high quality 
guidelines based on the scores (19); however, we have followed 
a recommended criteria to differentiate high and low quality 
CPGs (26). Additionally, the guidelines included in this 
review were published in English only, which has led to the 
exclusion of a substantial number of guidelines published in 
other languages. Half of the guidelines identified by this review 
obtained low AGREE II scores, which suggests more research 
is needed to develop clinically relevant recommendations in 
identification and management of frailty in the older adult 
population. 
Conclusion
This review summarized consistent recommendations for 
the assessment and management of frailty from CPGs to guide 
healthcare practitioners. A narrative synthesis of consistent 
key recommendations from the six selected CPGs, irrespective 
of their methodological quality judged with the AGREE II 
instrument, was done. Despite the limitations such as the lack of 
additional resources and variations recognized in each domain 
of the guidelines, our review demonstrates recommendations 
for assessing and managing frailty. Other barriers identified 
were the cost-effectiveness and how feasible recommendations 
were for implementation owing to factors such as fear 
avoidance, adherence to the comprehensive plan acknowledging 
patient’s cognition, their financial situation, physical ability 
or personal preferences. We identified many fields in which 
further research is needed to improve clinical relevance of 
CPGs in the identification and management of frailty such as 
cost effectiveness, difficulty of implementing, and applicability 
of recommendations to the older adult population aged 65 
and older, as well as researching how each CPG is being 
implemented, updated, and the clinical impact that they have. 
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